Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Atypical Hemolytic Uremic Syndrome (COMMUTE-a)
NCT04861259Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Started Oct 2021; status: active, not recruiting.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT04861259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861259.